Biomerica (BMRA) EBITDA Margin (2010 - 2026)
Biomerica (BMRA) reported EBITDA Margin of 131.51% for Q1 2026, down 2338.0% on a YoY basis from 5.88% in Q1 2025, and down 15.9% sequentially from 113.47% in Q4 2025.
Biomerica (BMRA) EBITDA Margin (2010 - 2026) Analysis & Trends
Biomerica (BMRA) has 17 years of EBITDA Margin data on file, last reported at 131.51% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 2338.0% year-over-year to 131.51%; the trailing twelve-month figure through Feb 2026 stood at 123.74% (down 3394.0% YoY), and the FY2025 full-year result was 96.72%, up 2086.0% from the prior year.
- EBITDA Margin slipped to 131.51% in Q1 2026, from 113.47% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 1.4% in Q1 2022 to a low of 208.81% in Q2 2025.
- A 5-year average of 110.3% and a median of 112.42% in 2022 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin surged 13027 bps in 2022 and tumbled 14720 bps in 2023, its largest moves.
- Tracing BMRA's EBITDA Margin over 5 years: stood at 112.42% in 2022, then increased by 9 bps to 102.62% in 2023, then jumped by 41 bps to 60.7% in 2024, then sank by 87 bps to 113.47% in 2025, then retreated by 16 bps to 131.51% in 2026.
- Business Quant data shows BMRA's EBITDA Margin at 131.51% in Q1 2026, 113.47% in Q4 2025, and 81.01% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Biomerica | 4.85 Mn | 3.51 Mn | -44,000.00 | -131.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -131.51% |
| Nov 30, 2025 | -113.47% |
| Aug 31, 2025 | -81.01% |
| May 31, 2025 | -208.81% |
| Feb 28, 2025 | -108.13% |
| Nov 30, 2024 | -60.70% |
| Aug 31, 2024 | -75.71% |
| May 31, 2024 | -136.92% |
| Feb 29, 2024 | -196.66% |
| Nov 30, 2023 | -102.62% |
| Aug 31, 2023 | -71.92% |
| May 31, 2023 | -165.70% |
| Feb 28, 2023 | -148.60% |
| Nov 30, 2022 | -112.42% |
| Aug 31, 2022 | -126.45% |
| May 31, 2022 | -33.13% |
| Feb 28, 2022 | -1.40% |
| Nov 30, 2021 | -24.31% |
| Aug 31, 2021 | -122.06% |
| May 31, 2021 | -163.40% |